What is BioSkryb?
BioSkryb Genomics, based in Durham, North Carolina, is a venture-backed entity specializing in proprietary Primary Template-directed Amplification (PTA) systems. These technologies are designed to deliver reproducible, high coverage breadth, and uniformity for sequencing applications, particularly those involving low or ultra-low input samples. The company's solutions are crucial for generating high-quality genetic analyses from limiting samples, supporting the advancement of genomic research and diagnostics.
How much funding has BioSkryb raised?
BioSkryb has raised a total of $11.5M across 1 funding round:
Angel/Seed
$11.5M
Angel/Seed (2020): $11.5M with participation from Anzu Partners and Wilson Sonsini Goodrich & Rosati
Key Investors in BioSkryb
Anzu Partners
Anzu Partners is an investment firm focused on breakthrough technologies in clean tech, industrial, and life sciences sectors. They provide strategic support and capital to help innovative companies like BioSkryb bring their solutions to market.
Wilson Sonsini Goodrich & Rosati
Wilson Sonsini Goodrich & Rosati is a prominent law firm providing legal services to technology and growth companies. Their involvement suggests a focus on the legal and corporate structuring aspects of BioSkryb's funding rounds.
What's next for BioSkryb?
The recent major strategic investment signals a pivotal growth phase for BioSkryb Genomics. This capital infusion is expected to accelerate the company's product development, expand its market reach, and further solidify its position in the competitive genomic technology landscape. The focus on strategic investment suggests potential collaborations or market penetration initiatives aimed at leveraging their PTA system for broader applications in life sciences and biotechnology.
See full BioSkryb company page
